Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer

Genes and Diseases

Volumn 2, Issue 1, 2015, Pages 4-12

  Knickelbein, Kyle ^a   Zhang, Lin ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Colorectal cancer; EGFR; KRAS; Synthetic lethality; Targeted therapy

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; PANITUMUMAB;

CANCER MORTALITY; CANCER THERAPY; COLORECTAL CANCER; GENE MUTATION; HUMAN; MUTANT; NONHUMAN; ONCOGENE K RAS; REVIEW; TREATMENT RESPONSE; TUMOR CELL; TUMOR GROWTH; UNITED STATES;

EID: 84978062508     PISSN: None     EISSN: 23523042     Source Type: Journal    
DOI: 10.1016/j.gendis.2014.10.002     Document Type: Review

References (98)

1. Cunningham D., Atkin W., Lenz H.J., et al. Colorectal cancer. Lancet 2010, 375:1030-1047.
2. Society AC Colorectal Cancer Facts & Figures 2014, American Cancer Society.
3. Markowitz S.D., Dawson D.M., Willis J., et al. Focus on colon cancer. Cancer Cell 2002, 1:233-236.
4. Brand T.M., Wheeler D.L. KRAS mutant colorectal tumors: past and present. Small GTPases 2012, 3:34-39.
5. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat Med 2004, 10:789-799.
6. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
7. Moran A., Ortega P., de Juan C., et al. Differential colorectal carcinogenesis: molecular basis and clinical relevance. World J Gastrointest Oncol 2010, 2:151-158.
8. Jancik S., Drabek J., Radzioch D., et al. Clinical relevance of KRAS in human cancers. J Biomed Biotechnol 2010, 2010:150960.
9. Lengauer C., Kinzler K.W., Vogelstein B. Genetic instability in colorectal cancers. Nature 1997, 386:623-627.
10. Grady W.M., Carethers J.M. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008, 135:1079-1099.
11. Prenen H., Tejpar S., Van Cutsem E. New strategies for treatment of KRAS mutant metastatic colorectal cancer. Clin Cancer Res 2010, 16:2921-2926.
12. Sullivan K.M., Kozuch P.S. Impact of KRAS mutations on management of colorectal carcinoma. Patholog Res Int 2011, 2011:219309.
13. Pylayeva-Gupta Y., Grabocka E., Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011, 11:761-774.
14. Giehl K. Oncogenic Ras in tumour progression and metastasis. Biol Chem 2005, 386:193-205.
15. Lowy D.R., Willumsen B.M. Function and regulation of ras. Annu Rev Biochem 1993, 62:851-891.
16. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003, 3:11-22.
17. Johnson L., Greenbaum D., Cichowski K., et al. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev 1997, 11:2468-2481.
18. Malumbres M., Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003, 3:459-465.
19. Karnoub A.E., Weinberg R.A. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008, 9:517-531.
20. Reuther G.W., Der C.J. The Ras branch of small GTPases: Ras family members don't fall far from the tree. Curr Opin Cell Biol 2000, 12:157-165.
21. Cooper G.M. The Cell: A Molecular Approach 2000, ASM Press; Sinauer Associates, Washington, D.C.; Sunderland, Mass. 2nd ed.
22. Buday L., Downward J. Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. Cell 1993, 73:611-620.
23. Shields J.M., Pruitt K., McFall A., et al. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol 2000, 10:147-154.
24. Pruitt K., Der C.J. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett 2001, 171:1-10.
25. Cox A.D., Der C.J. The dark side of Ras: regulation of apoptosis. Oncogene 2003, 22:8999-9006.
26. Lambert J.M., Lambert Q.T., Reuther G.W., et al. Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism. Nat Cell Biol 2002, 4:621-625.
27. Downward J. Ras signalling and apoptosis. Curr Opin Genet Dev 1998, 8:49-54.
28. Matallanas D., Romano D., Al-Mulla F., et al. Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras. Mol Cell 2011, 44:893-906.
29. Wang H.L., Lopategui J., Amin M.B., et al. KRAS mutation testing in human cancers: the pathologist's role in the era of personalized medicine. Adv Anat Pathol 2010, 17:23-32.
30. Perkins G., Pilati C., Blons H., et al. Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer. Pharmacogenomics 2014, 15:1043-1052.
31. Shirasawa S., Furuse M., Yokoyama N., et al. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993, 260:85-88.
32. Yun J., Rago C., Cheong I., et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009, 325:1555-1559.
33. Kim J.S., Lee C., Foxworth A., et al. B-Raf is dispensable for K-Ras-mediated oncogenesis in human cancer cells. Cancer Res 2004, 64:1932-1937.
34. Arena S., Isella C., Martini M., et al. Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers. Cancer Res 2007, 67:8468-8476.
35. Shao D.D., Xue W., Krall E.B., et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 2014, 158:171-184.
36. Kapoor A., Yao W., Ying H., et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell 2014, 158:185-197.
37. Viale P.H., Fung A., Zitella L. Advanced colorectal cancer: current treatment and nursing management with economic considerations. Clin J Oncol Nurs 2005, 9:541-552.
38. Meyerhardt J.A., Mayer R.J. Systemic therapy for colorectal cancer. N Engl J Med 2005, 352:476-487.
39. Venook A. Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist 2005, 10:250-261.
40. Institute NC Targeted Cancer Therapies 2014, National Cancer Institute.
41. Grothey A., Van Cutsem E., Sobrero A., et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013, 381:303-312.
42. El Zouhairi M., Charabaty A., Pishvaian M.J. Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents. Gastrointest Cancer Res 2011, 4:15-21.
43. Abrams T.A., Meyer G., Schrag D., et al. Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer. J Natl Cancer Inst 2014, 106:djt371.
44. Saif M.W. Colorectal cancer in review: the role of the EGFR pathway. Expert Opin Investig Drugs 2010, 19:357-369.
45. Singh A., Greninger P., Rhodes D., et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009, 15:489-500.
46. Mendelsohn J., Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000, 19:6550-6565.
47. Hagan S., Orr M.C., Doyle B. Targeted therapies in colorectal cancer-an integrative view by PPPM. EPMA J 2013, 4:3.
48. Messersmith W.A., Hidalgo M. Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one?. Clin Cancer Res 2007, 13:4664-4666.
49. Heinemann V., Douillard J.Y., Ducreux M., et al. Targeted therapy in metastatic colorectal cancer - an example of personalised medicine in action. Cancer Treat Rev 2013, 39:592-601.
50. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
51. Jonker D.J., O'Callaghan C.J., Karapetis C.S., et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357:2040-2048.
52. Shima F., Yoshikawa Y., Ye M., et al. In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction. Proc Natl Acad Sci U S A 2013, 110:8182-8187.
53. Douillard J.Y., Siena S., Cassidy J., et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 2014, 25:1346-1355.
54. Lievre A., Bachet J.B., Le Corre D., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66:3992-3995.
55. Benvenuti S., Sartore-Bianchi A., Di Nicolantonio F., et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007, 67:2643-2648.
56. Banck M.S., Grothey A. Biomarkers of resistance to epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal Cancer. Clin Cancer Res 2009, 15:7492-7501.
57. De Roock W., Claes B., Bernasconi D., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11:753-762.
58. Karapetis C.S., Khambata-Ford S., Jonker D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765.
59. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634.
60. Allegra C.J., Jessup J.M., Somerfield M.R., et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009, 27:2091-2096.
61. Bardelli A., Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010, 28:1254-1261.
62. Misale S., Arena S., Lamba S., et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med 2014, 6:224ra226.
63. Misale S., Yaeger R., Hobor S., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012, 486:532-536.
64. Misale S., Di Nicolantonio F., Sartore-Bianchi A., et al. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov 2014, 4:1269-1280.
65. Bettegowda C., Sausen M., Leary R.J., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014, 6:224ra224.
66. Diaz L.A., Williams R.T., Wu J., et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012, 486:537-540.
67. Valtorta E., Misale S., Sartore-Bianchi A., et al. KRAS geneamplification in colorectal cancer and impact on response toEGFR-targeted therapy. Int J Cancer 2013, 133:1259-1265.
68. Martini M., Vecchione L., Siena S., et al. Targeted therapies: how personal should we go?. Nat Rev Clin Oncol 2012, 9:87-97.
69. Kasper S., Breitenbuecher F., Reis H., et al. Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade. Oncogene 2013, 32:2873-2881.
70. Fisher G.H., Wellen S.L., Klimstra D., et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 2001, 15:3249-3262.
71. Sun Q., Burke J.P., Phan J., et al. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew Chem Int Ed Engl 2012, 51:6140-6143.
72. Maurer T., Garrenton L.S., Oh A., et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci U S A 2012, 109:5299-5304.
73. Ostrem J.M., Peters U., Sos M.L., et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013, 503:548-551.
74. Lim S.M., Westover K.D., Ficarro S.B., et al. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. Angew Chem Int Ed Engl 2014, 53:199-204.
75. Haluska P., Dy G.K., Adjei A.A. Farnesyl transferase inhibitors as anticancer agents. Eur J Cancer 2002, 38:1685-1700.
76. Cox A.D., Der C.J. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?. Biochim Biophys Acta 1997, 1333:F51-F71.
77. Gysin S., Salt M., Young A., et al. Therapeutic strategies for targeting ras proteins. Genes Cancer 2011, 2:359-372.
78. Zimmermann G., Papke B., Ismail S., et al. Small molecule inhibition of the KRAS-PDEdelta interaction impairs oncogenic KRAS signalling. Nature 2013, 497:638-642.
79. Fruman D.A., Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014, 13:140-156.
80. Neuzillet C., Tijeras-Raballand A., de Mestier L., et al. MEK in cancer and cancer therapy. Pharmacol Ther 2014, 141:160-171.
81. Engelman J.A., Chen L., Tan X., et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008, 14:1351-1356.
82. Yuan T.L., Fellmann C., Lee C.S., et al. Development of siRNA payloads to target KRAS-mutant Cancer. Cancer Discov 2014, 4:1182-1197.
83. Lamba S., Russo M., Sun C., et al. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. Cell Rep 2014, 8:1475-1483.
84. Vigil D., Cherfils J., Rossman K.L., et al. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?. Nat Rev Cancer 2010, 10:842-857.
85. Wang Y., Kaiser C.E., Frett B., et al. Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators. J Med Chem 2013, 56:5219-5230.
86. Berndt N., Hamilton A.D., Sebti S.M. Targeting protein prenylation for cancer therapy. Nat Rev Cancer 2011, 11:775-791.
87. Friday B.B., Adjei A.A. K-ras as a target for cancer therapy. Biochim Biophys Acta 2005, 1756:127-144.
88. Stephen A.G., Esposito D., Bagni R.K., et al. Dragging ras back in the ring. Cancer Cell 2014, 25:272-281.
89. Ferrari E., Lucca C., Foiani M. A lethal combination for cancer cells: synthetic lethality screenings for drug discovery. Eur J Cancer 2010, 46:2889-2895.
90. Chan D.A., Giaccia A.J. Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov 2011, 10:351-364.
91. Kaelin W.G. Synthetic lethality: a framework for the development of wiser cancer therapeutics. Genome Med 2009, 1:99.
92. Luo J., Emanuele M.J., Li D., et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009, 137:835-848.
93. Barbie D.A., Tamayo P., Boehm J.S., et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009, 462:108-112.
94. Scholl C., Frohling S., Dunn I.F., et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009, 137:821-834.
95. Wang Y., Ngo V.N., Marani M., et al. Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells. Oncogene 2010, 29:4658-4670.
96. Singh A., Sweeney M.F., Yu M., et al. TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell 2012, 148:639-650.
97. Kumar M.S., Hancock D.C., Molina-Arcas M., et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 2012, 149:642-655.
98. Corcoran R.B., Cheng K.A., Hata A.N., et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 2013, 23:121-128.